Patient Experiences of Bullous Pemphigoid: Symptoms and Health-Related Quality of Life Impacts
The conceptual model presented here can be the basis for endpoint selection in studies of new therapies for BP.
Authors
- Nicolette C. Bishop (ORCID: https://orcid.org/0000-0001-6221-3907)
- Neil J. Korman (ORCID: https://orcid.org/0000-0002-9785-3442)
- Oren Meyers (ORCID: https://orcid.org/0000-0002-0085-1732)
- Julie Bailey (ORCID: https://orcid.org/0009-0004-4111-7157)
- Caroline Roberts (ORCID: https://orcid.org/0000-0002-9819-1903)
- Calvin N. Ho (ORCID: https://orcid.org/0000-0002-3360-9651)
- Lila Bahadori
- Marc Yale (ORCID: https://orcid.org/0009-0006-6722-3569)
Institutions
- University Hospitals of Cleveland (US)
- IQVIA (United States) (US)
- AstraZeneca (France) (FR)
- AstraZeneca (Spain) (ES)
- IQ Solutions (US)
- National Patient Safety Foundation (US)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1007/s13555-025-01424-z
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca